Humacyte (HUMA) Short term Debt (2020 - 2025)

Humacyte (HUMA) posted quarterly Short term Debt of $3.1 million for Q3 2025, up 45.18% quarter-over-quarter from $2.1 million in Q2 2025.

Humacyte (HUMA) Short term Debt (2020 - 2025) Analysis & Trends

Humacyte (HUMA) has reported Short term Debt for 6 consecutive years, with $3.1 million the latest figure, recorded in Q3 2025.

In Q3 2025, Short term Debt changed N/A year-over-year to $3.1 million; the TTM figure through Sep 2025 stood at $3.1 million (changed N/A YoY), while the FY2024 annual figure was $885000.0, changed N/A from the prior year.
Short term Debt improved to $3.1 million in Q3 2025 per HUMA's latest filing, from $2.1 million in the prior quarter.
Across five years, Short term Debt topped out at $12.9 million in Q1 2023 and bottomed at $10000.0 in Q1 2021.
Historically, Short term Debt has averaged $4.2 million across 5 years, with a median of $3.1 million in 2025.
Annual changes were most pronounced in 2021 — Short term Debt soared 89632.35% — and 2022, when it advanced 10.21%.
Humacyte's Short term Debt stood at $3.9 million in 2021, then jumped by 120.39% to $8.6 million in 2022, then surged by 50.01% to $12.9 million in 2023, then tumbled by 93.12% to $885000.0 in 2024, then soared by 247.12% to $3.1 million in 2025.
Business Quant data shows HUMA's Short term Debt at $3.1 million in Q3 2025, $2.1 million in Q2 2025, and $1.7 million in Q1 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn
10	Humacyte	158.12 Mn	158.12 Mn	-825,000.00

Download Data